- Vaccine Tied to Reduced Risks for Heart Attack, Stroke MedPage Today
- Immunogenicity and safety of a recombinant gE-Fc fusion protein subunit vaccine for herpes zoster in adults ≥50 years of age: a randomised, active-controlled, non-inferiority trial Nature
- Beijing Luzhu Biotech Announces Positive Trial Results for LZ901 Vaccine TipRanks